OliX Pharmaceuticals Inc (KOSDAQ:226950), a pharmaceutical company based in South Korea, said on Wednesday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to develop its RNAi therapeutic OLX10212 for the treatment of age-related macular degeneration (AMD).
OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the phase 1 study is to evaluate the safety and tolerability of OLX10212 in patients with AMD.
With the FDA approval of the IND application for OLX10212, OliX has initiated clinical trials for two investigational therapeutic programmes in the US. In June 2022 the company completed patient enrolment for the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients